



“Idiopathic inflammatory myopathies and the lung.” Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien, Isabelle Durieu and Vincent Cottin.

***Eur Respir Rev* 2015; 24: 216–238.**

Unfortunately, there was a typographic error in this article. The sentence that read:

“It is administered with two doses of 700 mg or 1000 mg 2 weeks apart, or with four weekly infusions of 375 mg·m⁻².”

should have read as follows:

“It is administered with two doses of 700 mg·m⁻² or 1000 mg 2 weeks apart, or with four weekly infusions of 375 mg·m⁻².”

The online version of the article has been amended to reflect this correction.

Eur Respir Rev 2015; 24: 545 | DOI: 10.1183/16000617.50002015



“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher.

***Eur Respir Rev* 2015; 24: 58–64.**

Unfortunately, there was a typographic error in this article. The sentence that read:

The mean daily dose of pirfenidone for all subjects during this time was 2332 mg·day⁻¹, with the maximum possible daily dose being 2403 mg·day⁻¹.

should have read as follows:

The mean daily dose of pirfenidone for all subjects during this time was 2070 mg·day⁻¹, with the maximum possible daily dose being 2403 mg·day⁻¹.

The online version of the article has been amended to reflect this correction.

Eur Respir Rev 2015; 24: 545 | DOI: 10.1183/09059180.50011514